{
    "nct_id": "NCT06895473",
    "official_title": "A Phase 2 Study of Prophylactic IT Chemotherapy to Prevent High-Grade Chimeric Antigen Receptor (CAR) T-Cell-Associated Neurotoxicity Syndrome",
    "inclusion_criteria": "* Written informed consent. Participant or legally authorized representative (LAR) must provide written informed consent prior to any study-specific procedures or interventions\n* Age ≥ 18 years. All genders, races, and ethnic groups will be included\n* Must be receiving SOC Yescarta® or Tecartus® in the inpatient setting\n* Agree to adhere to institutional guidelines for contraception during the first 30 days post CAR-T\n\n  * Rationale for eligibility criteria based on contraception and pregnancy (both participants and partners of a sperm-producing participant): It shall be known to all participants that the effects of CAR-T or IT chemotherapy on the developing human fetus are unknown. For this reason, persons of reproductive potential must agree to use adequate contraception. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Platelet count > 50,000/mm^3 (μL)\n* Adequate coagulation tests including international normalized ratio (INR) < 1.6 and fibrinogen > 100\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active/concurrent diagnosis of any central nervous system (CNS) hematologic malignancy\n* History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement\n* Known history of hypersensitivity to IT chemotherapy\n* Subject has a contraindication to LP including:\n\n  * Presence of a posterior fossa mass\n  * Skin infection near puncture site\n  * Uncorrected bleeding diathesis\n  * Suspicion of increased intracranial pressure\n  * Acute spinal cord trauma\n* Subject is receiving an antiplatelet and/or anticoagulant that cannot be held prior to LP according to best available evidence\n* Known bleeding disorders\n* Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgement, make the participant inappropriate for study participation or would put the participant at risk",
    "miscellaneous_criteria": ""
}